Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more

Conditions: HIV Infections
Interventions: HIV-1 DNA vaccine with protein vaccine boost; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: HIV Infections
Interventions: PENNVAX-B, IL-12 DNA plasmids; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: HIV-1-infection
Interventions: PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000; Biological · Device
Lead sponsor: Steven Deeks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: HIV Infections
Interventions: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more

Conditions: HIV
Interventions: 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV, TBC-MVA and TBC-FPV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 4
States / cities: Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more

Conditions: HIV Infections
Interventions: PennVax B, IL-12, IL-15; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: HIV Infections
Interventions: PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV
Interventions: rcAd26.MOS1.HIV-Env 1x10^8 vp, rcAd26.MOS1.HIV-Env 1x10^9 vp, rcAd26.MOS1.HIV-Env 1x10^10 vp, rcAd26.MOS1.HIV-Env 1x10^11 vp; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 40 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Conditions: Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Interventions: VRC-HIVRGP096-00-VP, Alum Adjuvant; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, HIV Seronegativity
Interventions: Env 2-3; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 3
States / cities: Rochester, New York • Nashville, Tennessee • Seattle, Washington

Conditions: HIV Infections
Interventions: rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1994
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Profectus HIV MAG pDNA vaccine, IL-12, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more

Conditions: HIV-1-infection
Interventions: INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: HIV Infections
Interventions: pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: HIV Infections
Interventions: EP HIV-1043, EP HIV-1090; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Rochester, New York

Conditions: HER2-positive Breast Cancer
Interventions: Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Goodyear, Arizona

Search by objective public record fields.

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

Therapeutic Vaccination in Treated HIV Disease

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

Fasting on Newly Diagnosed Breast Cancer